$PMCB
PharmaCyte Biotech, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$0.309
▼-6.82%-$0.023
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonatePharmaCyte Biotech, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is PMCB down today? It is at $0.309 (-6.82%), and our scanner flagged it 2 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment PMCB spikes, and full due diligence on PMCB — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $PMCB 2 times in the last 30 days. Create a free account to track $PMCB, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on PMCB from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for PMCB today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystChange of Accountant, from the latest SEC filing. Read it →Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Schechter Jonathan Director | Bought (open market) | +20K 0.2% of company | added 12% | 193K | $17K at $0.840 | Jan 7, 26 |
Silverman Joshua Officer | Bought (open market) | +40K 0.4% of company | added 11% | 416K | $33K at $0.830 | Jan 7, 26 |
Schechter Jonathan Director | Bought (open market) | +20K 0.2% of company | added 13% | 173K | $16K at $0.790 | Jan 6, 26 |
Silverman Joshua Officer | Bought (open market) | +30K 0.3% of company | added 8.7% | 376K | $24K at $0.790 | Jan 6, 26 |
Schechter Jonathan Director | Bought (open market) | +20K 0.2% of company | added 15% | 153K | $16K at $0.780 | Jan 5, 26 |
Silverman Joshua Officer | Bought (open market) | +30K 0.3% of company | added 9.5% | 346K | $23K at $0.780 | Jan 5, 26 |
Abecassis Michael M Director | Acquired (grant/award) | +38K 0.3% of company | added 100% | 39K | n/a | Dec 12, 25 |
Abecassis Michael M Director | Sold (automatic/other) | -17K 0.2% of company | sold 43% | 22K | $17K at $1.02 | Dec 12, 25 |
Schechter Jonathan Director | Acquired (grant/award) | +150K 1.4% of company | added 100% | 200K | n/a | Dec 12, 25 |
Schechter Jonathan Director | Sold (automatic/other) | -68K 0.6% of company | sold 34% | 133K | $69K at $1.02 | Dec 12, 25 |
Silverman Joshua Officer | Acquired (grant/award) | +575K 5.4% of company | n/a | 575K | n/a | Dec 12, 25 |
Silverman Joshua Officer | Sold (automatic/other) | -259K 2.4% of company | sold 45% | 316K | $264K at $1.02 | Dec 12, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on PMCB from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for PMCB today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
PMCB last traded at $0.309, down 6.82% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
PharmaCyte Biotech, Inc. Common Stock (PMCB) is next expected to report earnings on Thursday, December 17, 2026, about 47 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The PMCB Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged PMCB 2 times in the last 30 days.
PMCB (PharmaCyte Biotech, Inc. Common Stock) trades on XNAS, with a market cap of about $3M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge PMCB for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$PMCB discussion
Sign in to ask a question or join the discussion.